Traditional Chinese Medicine for Essential Hypertension: A Clinical Evidence Map

Abstract

We systematically retrieved and summarised clinical studies on traditional Chinese medicine (TCM) for the prevention and treatment of essential hypertension (EH) using the evidence map. We aimed to explore the evidence distribution, identify gaps in evidence, and inform on future research priorities. Clinical studies, systematic reviews, guidelines, and pathway studies related to TCM for the prevention and treatment of EH, published between January 2000 and December 2019, were included from databases CNKI, WanFang Data, VIP, PubMed, Embase, and Web of Science. The distribution of evidence was analysed using text descriptions, tables, and graphs. A total of 9,403 articles were included, including 5,920 randomised controlled studies (RCTs), 16 guidelines, expert consensus and path studies, and 139 systematic reviews (SRs). The articles publishing trend increased over time. This study showed that the intervention time of TCM was concentrated at 4–8 weeks, mainly through Chinese herbal medicine (CHM) for the prevention and treatment of elderly hypertension and the complications. A Measurement Tool to Assess Systematic Reviews (AMSTAR) scores of the included reviews ranged from 2 to 10. Most of the SRs had a potentially positive effect (n = 120), mainly in 5–8 score. Primary studies and SRs show potential benefits of TCM in lowering blood pressure, lowering the TCM syndrome and symptom differentiation scores (TCM-SSD scores), improving the total effective rate, and reducing the adverse events. The adjunctive effect of TCM on improving the total effective rate, lowering the blood pressure, lowering the TCM-SSD scores, and lowering the adverse effects was only supported by low-quality evidence in this research. The evidence map was used to show the overall research on TCM for the treatment of EH; however, due to the existing problems of the primary studies, the current research conclusion needs further research with higher quality and standardisation.

Prevalence of Use of Traditional, Complementary and Alternative Medicine by the General Population: A Systematic Review of National Studies Published from 2010 to 2019

“…Ambiguities also arise where TM preparations/products (i.e. traditionally processed herbal extracts/decoctions) are used to treat ‘Western’ medicine diagnoses, such as hypertension and type 2 diabetes mellitus [ 71 , 72 ], and at the 'food–medicine interface/border', where products such as herbal teas (e.g. green/black tea) and 'superfoods' (e.g.…”

Investigating the effects and mechanisms of Erchen Decoction in the treatment of colorectal cancer by network pharmacology and experimental validation

“…The traditional Chinese herbal medicine formulas have low toxicity and have multi-target activity for preventing or treating various diseases, including cardiovascular disease ( Zhang et al, 2020b ), endocrine disease ( Zhang et al, 2020a ), hematologic disease ( Chiu et al, 2021 ) and cancers ( Lu et al, 2021 ), etc. The occurrence and development of CRC is thought to be the results of a combination of multiples genes, factors, stages ( Li et al, 2015 ), which indicates that the multi-component and multi-target activity of Chinese medicine seems to be more beneficial to the treatment of CRC individuals ( Wang et al, 2021b ; Sun et al, 2021 ).…”

Clinical Application of Traditional Chinese Medicine Therapy for Type 2 Diabetes Mellitus: An Evidence Map

“…Therefore, this study aims to reevaluate systematic reviews and meta-analyses, adopt the evidence mapping method, integrate the evidence from various research, and comprehensively sort out the problems in the research topic, thus depicting the whole picture of the research field [ 6 ]. No evidence map of T2DM has been published in the field of TCM.…”

“…(6) Primary outcomes included HbA1c, 2-h PBG, and FBG; secondary outcomes included BMI, HDL-C, HOMA-IR, LDL-C, TC, TG, INS, 2 h postprandial insulin, time to target blood glucose, average insulin dose, ISI, HOMA-β, hypoglycemia occurrence frequency/rate, clinical efficacy, TCM syndrome, etc (7). No limitations were imposed on the study design or publication type.2.3.…”